Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M564Revenue $M1.3Net Margin (%)-3,000.3Z-Score39.3
Enterprise Value $M438EPS $-0.3Operating Margin %-3,048.0F-Score4
P/E(ttm))0Cash Flow Per Share $-0.7Pre-tax Margin (%)-3,000.3Higher ROA y-yN
Price/Book4.110-y EBITDA Growth Rate %-8.8Quick Ratio18.1Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-23.4Current Ratio18.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-30.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-32.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M157ROI % (ttm)-57.9Gross Margin Increase y-yN

Gurus Latest Trades with GERN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
GERNJean-Marie Eveillard 2014-09-30 Reduce-0.01%$2.12 - $3.014
$ 3.8456%Reduce -38.05%2,198,124
GERNJean-Marie Eveillard 2014-03-31 Add0.01%$1.6 - $5.4
$ 3.84-5%Add 46.43%3,054,252
GERNJohn Burbank 2014-03-31 Buy $1.6 - $5.4
$ 3.84-5%New holding, 25000 sh.25,000
GERNJean-Marie Eveillard 2013-03-31 Add$1.01 - $1.64
$ 3.84178%Add 36.91%2,410,934
GERNGeorge Soros 2011-03-31 Sold Out $4.44 - $5.07
$ 3.84-18%Sold Out0
GERNJean-Marie Eveillard 2010-12-31 Add0.03%$4.46 - $6.02
$ 3.84-27%Add 74.8%2,570,500
GERNGeorge Soros 2010-12-31 Buy $4.46 - $6.02
$ 3.84-27%New holding, 26500 sh.26,500
GERNJean-Marie Eveillard 2010-06-30 Add0.02%$4.67 - $5.81
$ 3.84-25%Add 77.56%1,420,500
GERNJean-Marie Eveillard 2010-03-31 Add0.03%$4.97 - $6.21
$ 3.84-31%Add 204.8%800,000
GERNJean-Marie Eveillard 2009-12-31 Add0.02%$4.91 - $6.69
$ 3.84-31%Add 556.18%262,471
GERNJean-Marie Eveillard 2008-12-31 Add$2.46 - $4.39
$ 3.8410%Add 23.52%308,800
GERNJean-Marie Eveillard 2008-06-30 Add$3.28 - $4.86
$ 3.84-8%Add 25.42%222,000
GERNJean-Marie Eveillard 2008-03-31 Add$4.11 - $4.99
$ 3.84-15%Add 82.47%177,000
GERNJean-Marie Eveillard 2007-12-31 Add$5.62 - $7.56
$ 3.84-41%Add 25.97%97,000
GERNJean-Marie Eveillard 2007-09-30 Reduce$5.61 - $7.85
$ 3.84-43%Reduce -71.38%77,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GERN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GERN John Burbank 2014-09-3025,0000.020
GERN Jean-Marie Eveillard 2014-09-302,198,1241.40.01-38.05%
Premium Most recent portfolio changes are included for Premium Members only!

GERN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-05-29Sell4,826$2.171.43view
Bloom Olivia KyusukEVP, CFO 2014-05-29Sell3,379$2.171.43view
BRADBURY DANIELDirector 2014-05-09Buy142,776$1.75105.71view
Bloom Olivia KyusukEVP, CFO 2014-04-01Sell7,435$2.1369.01view
BEHRS MELISSA KELLYEVP Portfolio & Alliance Mgmt 2014-04-01Sell12,310$2.1369.01view
SCARLETT JOHN APresident and CEO 2013-04-01Buy50,000$1.03249.51view
BEHRS MELISSA KELLYSVP Alliance and Prog Mgmt 2013-01-17Sell28,292$1.65118.18view
Kelsey Stephen MichaelEVP, R&D Head, CMO 2012-05-30Sell9,300$1.37162.77view
EARP DAVIDSVP, Corp Transactions 2012-05-30Sell27,155$1.37162.77view
Bloom Olivia KyusukVP, Chief Acctg Officer 2012-05-30Sell11,029$1.37162.77view

Press Releases about GERN :

    Quarterly/Annual Reports about GERN:

    News about GERN:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
    Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
    Geron: Buyer Beware Oct 13 2010 
    Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
    Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
    Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
    Geron Corp (GERN): Stock of the Day Mar 10 2009 
    Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
    The Next Boom Emerges Nov 23 2008 

    More From Our Partners
    Midday Gainers / Losers Nov 21 2014 - SEEKINGALPHA

    More From Other Websites
    Strong On High Relative Volume: Geron (GERN) Nov 21 2014
    The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Nov 20 2014
    Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014
    Can the Rally in Geron (GERN) Shares Continue? Nov 19 2014
    GERON CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 18 2014
    Incyte Building Blockbuster Drug One Disease At A Time Nov 17 2014
    Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal Nov 17 2014
    Strength Seen in Geron (GERN): Stock Surges 19.5% Nov 17 2014
    Geron to Present at the Stifel Healthcare Conference Nov 14 2014
    Geron Collaborates with J&J for Imetelstat Nov 14 2014
    All in all, another solid week for U.S. equities... Nov 14 2014
    Geron to Present at the Stifel Healthcare Conference Nov 14 2014
    GERON CORP Financials Nov 14 2014
    What Licensing Imetelstat Will Mean for Geron Nov 14 2014
    Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat Nov 14 2014
    Geron Corp Announces Global Strategic Collaboration with Janssen Biotech, Inc. Call scheduled for... Nov 14 2014
    Geron sells last drug in pipeline to J&J unit Nov 13 2014
    Geron could get $935M in blood disorder drug deal Nov 13 2014
    Geron could get $935M in blood disorder drug deal Nov 13 2014
    Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson Nov 13 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial